AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment ... of the fast-growing dopamine D2/D3 receptor partial agonist, one of the star ...

Unlike traditional antipsychotic medications that target dopamine receptors, Cobenfy utilizes a combination of xanomeline ... Currently approved treatments include Vanda Pharmaceuticals' Fanapt, ...

The drug is the first approved antipsychotic that targets cholinergic receptors as opposed to dopamine ... Pharmaceuticals’ Fanapt, AbbVie’s Vraylar and generic drugs such as olanzapine ...

Seroquel and Abilify which tend to work by inhibiting D2 dopamine or 5HT-2A Serotonin receptors rather than stimulating muscarinic receptors. All three of these treatments made peak sales of >$5bn ...

The drug is the first approved antipsychotic that targets cholinergic receptors as opposed to dopamine receptors ... Currently approved antipsychotic drugs include Vanda Pharmaceuticals' Fanapt, ...

The drug is the first approved antipsychotic that targets cholinergic receptors as opposed to dopamine ... Vanda Pharmaceuticals' Fanapt, AbbVie's Vraylar and generic drugs such as olanzapine ...

Process Governor is a utility that automates the management of Windows processes and services by adjusting their priorities, I/O priorities, and core affinity according to user-defined rules ...

Vraylar is a prescription drug that’s used to treat certain mental health conditions, such as bipolar I disorder. Vraylar can cause side effects that range from mild to serious. Examples include ...

Vraylar (cariprazine) is a prescription drug that’s used to treat certain mental health conditions, such as schizophrenia. The drug comes as a capsule that you swallow. It’s usually taken once ...

Gift 5 articles to anyone you choose each month when you subscribe. Pathology giant Healius, capitalised at $1.17 billion, has agreed to sell its Lumus radiology business to pan-Asian buyout group ...